285 breast cancer patients will receive a new treatment, called Trastuzumab, to protect them against viruses and bacteria for a year.
After several studies on the drug, Caja Costarricense del Seguro Social (CCSS) approved its purchase. According to María del Rocío Sáenz, president of the institution, an annual $8.5 million investment will be made. The acquisition of 5,300 bottles was authorized. The drug is applied subcutaneously and will be prescribed by all hospitals that have an oncologic service.
Patients using Trastazumab increased their survival rates to 5 years. The drug is used every 22 days and it is applied in the hospital after surgery, chemotherapy or radiotherapy sessions.